The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

A Greenwood Village mental health clinic said they are the first to provide ketamine therapy that they say is affordable to ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato ... to treat depression. Ketamine has long been seen as a potential breakthrough in depression treatment, despite safety ...

Through Colorado’s Path4EMS program, a mental health clinic reduces ketamine infusion costs from $400 to $150, making treatment more accessible for first responders ...

In a new study on mice, an experimental antibody treatment reduced the lingering after-effects of head injuries.

Ketamine is often viewed more as a party drug than a medicine. One Columbia clinic is using the drug to help patients with ...

Current treatments ... Dosing and Efficacy Profile Ketamine is commonly administered via intravenous infusion, although other routes, such as nasal and oral, have been explored.

A new study suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI). By studying the effects of the nasal anti-CD3 in a ...

making the nasal spray the only authorized standalone therapy for treatment-resistant depression. According to Reilly, IV and intramuscular ketamine have not received FDA approval because they ...

Esketamine, the ketamine-derived nasal spray sold under the brand name Spravato (esketamine), is indicated for patients with treatment-resistant depression. In October 2023, the FDA warned about ...